Collaborative multidisciplinary workshop report: clinical antimicrobial trials for primary and secondary prevention

H Rosen1, J B Muhlestein, J Bartlett

  • 1Department of Medicine, Harborview Medical Center, University of Washington, Seattle, WA, USA.

Insights

This review assesses the need for more antibiotic trials in preventing atherosclerotic cardiovascular disease. It also proposes future trial designs and emphasizes collaboration in research.

Area of Science:

  • Cardiovascular Medicine
  • Infectious Diseases
  • Clinical Trials

Background:

  • Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of mortality worldwide.
  • The role of antimicrobial agents in the primary or secondary prevention of ASCVD is not fully established.
  • Existing research has not definitively determined the necessity of further clinical antibiotic trials in this domain.

Purpose of the Study:

  • To evaluate the need for additional clinical antibiotic trials focused on the primary and/or secondary prevention of atherosclerotic cardiovascular disease.
  • To propose potential designs for future clinical trials investigating antimicrobial interventions for ASCVD.
  • To define the significance and structure of collaborative efforts in addressing research questions related to ASCVD and antimicrobials.

Main Methods:

  • The working group convened to analyze existing literature and clinical evidence.
  • Discussions focused on identifying gaps in current knowledge regarding antibiotic use in ASCVD prevention.
  • Expert consensus was sought to formulate recommendations for future research methodologies and collaborative frameworks.

Main Results:

  • The evaluation indicated a need for further rigorous clinical trials to ascertain the efficacy of antimicrobial agents in ASCVD prevention.
  • Specific trial designs were conceptualized, considering patient populations, intervention parameters, and outcome measures.
  • The critical role of interdisciplinary collaboration was highlighted for enhancing the scope and impact of future research.

Conclusions:

  • Additional well-designed clinical antibiotic trials are warranted to explore the potential of antimicrobial therapies in ASCVD prevention.
  • Future research should incorporate innovative trial designs and foster robust collaborations among researchers, clinicians, and institutions.
  • A collaborative approach is essential for efficiently answering complex research questions in this field.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...